Compare HIPO & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | DNA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | 540 | 485 |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.1M | 599.0M |
| IPO Year | N/A | N/A |
| Metric | HIPO | DNA |
|---|---|---|
| Price | $29.00 | $10.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $38.67 | $8.50 |
| AVG Volume (30 Days) | 143.7K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $22.33 | N/A |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.08 | $5.37 |
| 52 Week High | $38.98 | $17.58 |
| Indicator | HIPO | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | 65.46 |
| Support Level | $24.68 | $7.59 |
| Resistance Level | $29.08 | $10.66 |
| Average True Range (ATR) | 1.11 | 0.77 |
| MACD | 0.44 | 0.17 |
| Stochastic Oscillator | 84.38 | 78.11 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.